周田彦 博士 教授 博士生导师
电话：(10)-**
电子信箱：tianyanzhou@bjmu.edu.cn
简历：
分别于1992、1998、2006年在北京大学药学院获得学士、硕士及博士学位。曾到香港理工大学(2002-2004)和美国奥克拉荷马州立大学(2007-2008)作访问研究。1998年后在北京大学药学院药剂学系工作。
长期从事定量药理学以及药物代谢酶相关研究和应用，是北京大学/辉瑞公司定量药理学高级培训中心核心成员。现任北京大学药学院教授、博士生导师，中国药理学会定量药理学专业委员会委员，国家自然科学基金及北京市等省部级自然科学基金评审专家，国家食品与药品管理局新药评审专家，中国临床药理学与治疗学杂志编委，以及10余个国内外相关专业期刊的评审。
主持多项国家自然科学基金及北京市/教育部自然科学基金项目。发表论文90余篇，编写教材与专著6部，申请专利5项。主讲课程有本科生《生物药剂学与药物动力学》以及研究生《高等药物动力学》。
研究方向：
定量药理学（主要包括基于机制的药物动力学/药效动力学(PK/PD)，群体药物动力学）；药物代谢酶诱导机理及功能。
Dr. Tianyan Zhou received her Bachelor, Master, and PhD degree from School of Pharmaceutical Sciences, Beijing Medical University/Peking University in 1992, 1998, and 2006, respectively. She started working at School of Pharmaceutical Sciences, Peking University in 1998, also she worked as Research Associate in The Hong Kong Polytechnic University from 2002 to 2004, and as Visiting Scholar in Oklahoma State University from 2007 to 2008 in USA.
Dr. Zhou’s research focuses on pharmacometrics and drug metabolizing enzymes. She is Full Professor and Ph.D Supervisor in School of Pharmaceutical Sciences, Peking University. Dr. Zhou is a member of Chinese Pharmacology Society Quantitative Pharmacology Professional Committee and Peking University/Pfizer Pharmacometrics Education Center. She serves as an evaluation expert for Natural Science Foundation of China (NSFC), provincial foundations as well as Center for Drug Evaluation, CFDA. She is an editorial member of Chinese Journal of Clinical Pharmacology and Therapeutics and a reviewer of more than 10 academic journals.
Dr. Zhou hosts several research projects including Programs of NSFC and Ministry of Education. She has published more than 90 research papers and 6 book chapters, and has applied for 5 patents. Her primary teaching courses are Biopharmaceutics and Pharmacokinetics (for undergraduate) and Advanced Pharmacokinetics (for MS and Ph.D).
Research Interests:
1. Pharmacometrics (including Mechanism-based Pharmacokinetics/ pharmacodynamics and Population Pharmacokinetics)
2. Functions and regulation mechanisms of drug metabolizing enzymes.
Selected Publications
1. Li, J; Chen, R; Yao, QY; Liu, SJ; Tian, XY; Lu, W*; Zhou, TY*. Semi-mechanism-based pharmacokinetic-pharmacodynamic model for characterizing time-dependent pharmacokinetics of dexamethasone and its efficacy in the treatment of breast cancer. Acta Pharmacol Sin. 2018, online.
2. Chen, WJ; Chen, R; Li, J; Fu, Y; Yang, L; Su, H; Yao, Y; Li, L;Zhou, TY*; Lu, W*. Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models. J Pharmacol Exp Ther . 2018, 364(1), 13-25.
3. Hao, FR; Wang, SY; Zhu, X; Xue, JS; Li, JY; Wang, LJ; Li, J Lu, W; Zhou, TY*. Pharmacokinetic- pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft. Pharm Res. 2017, 34, 408-418.
4. Li, J; Yao, QY; Xue, JS; Wang, LJ; Yuan, Y; Tian, XY; Su, H; Wang, SY; Chen, WJ; Lu, W*;Zhou, TY*. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta Pharmacol Sin. 2017, 38(9), 1282-1296.
5. Yao, QY; Li, J; Yao,Y; Chen, R; Chen, WJ; Su, H, Yang, L; Xue, JS; Lu, W; Zhou, TY*. A highly sensitive LC-MS/MS method for the determination of 21-hydroxy deflazacort in nude mice plasma and its application to a pharmacokinetic study. J Chinese Pharm Sci . 2017, 26(6), 404-412.
6. Li, JY; Ren, YP; Yuan, Y; Ji SM; Zhou, SP; Wang, LJ; Mou Z; Li, L; Lu, W, Zhou, TY*. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice. Acta Pharmacol Sin. 2016, 37(7), 930-940.
7. Wang, LJ; Li, J; Hao, FR; Yuan, Y; Li, JY; Lu, W;Zhou, TY*. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen. Acta Pharmacol Sin. 2016, 37(6), 845-856.
8. Ji, XW; Ji, SM; Li, RT; Wu, KH; Zhu, X; Lu, W*; Zhou, TY*. Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in breast cancer. Acta Pharmacol Sin, 2016, 37(6). 825-833.
9. Li, X; Chen Y; Zhao W; Lu, W*; Zhou, TY*. Pharmacokinetic/Pharmacodynamic Analysis of Metformin using Different in Diabetic Rats. Drug Res. 2016, 66(10), 547-554.
10. Mou, ZZ; Wang, SY; Su, QH; Yuan, Y; Li, JY; Wang, LJ; Yao, QY; Ji, SM; Lu, W*; Zhou, TY*. Cabozantinib enhances the response of NSCLC cells with wild-type EGFR to erlotinib and pharmacodynamic modeling of their sequential combinations. J Chinese Pharm Sci. 2016, 25(11), 799-813.
11. Hua, M; Ji, XW; Li, RT; Ji, SM; Li, J; Yao, QY; Wang, LJ; Hao, FR; Lu, W; Zhou, TY*. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft. J Chinese Pharm Sci. 2016, 25(7), 502-511.
12. Ma, YH; Li, J; Su, QH; Chen, WJ; Lu, W*; Zhou, TY*. A liquid chromatography-tandem mass spectrometric method for the determination of axitinib in nude mouse plasma: Development, validation and application to a pharmacokinetic study, J Chinese Pharm Sci. 2016, 25(5), 342-350.
13. Yuan, Y; Zhou, X; Ren, YP; Zhou, SP, Wang, LJ; Ji, SM; Hua, M; Li L; Lu, W; Zhou, TY*. Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer. J Pharm Sci . 2015, 104(12), 4399–4408.
14. Ji, XW; Chen, GP; Song, Y; Hua, M; Wang, LJ; Li, L; Yuan, Y; Wang, SY; Zhou, TY*; Lu, W. Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208. Acta Pharmacol Sin. 2015, 36(10), 1246-55.
15. Wang, SY; Mou, ZZ; Ma, YH; Li, J; Li, JY; Ji, XW; Wu, KH; Li, L; Lu, W; Zhou, TY*. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: involvement of eradicating cancer stem-like cells. Biochem Pharmacol. 2015, 95(2), 98-109.
16. Ji, XW; Zhou, TY; Lu, Y; Wei, MJ, Lu; W; Cho, William Cs. Breast cancer treatment and sulfotransferase. Expert Opinion on Therapeutic Targets. 2015, 19(6), 821-34.
17. Li, J; Yuan, Y; Fan, R; Su, QH; Wang, SY; Zhou, TY*; Lu, W. A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study. J AOAC INT . 2015, 98(4), 921-926.
18. Li, JY; Li, J; Wang, SY; Yuan, Y; Su, QH; Lu, W; Zhou, TY*. Simultaneous determination of sunitinib and its active metabolites N-desethylsunitinib (SU12662) in nude mice plasma by liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Chinese Pharm Sci. 2015, 24(4), 217-224.
19. Yuan, Y; Zhou, X; Li, J; Ye, S., Ji, XW; Li, L; Zhou, TY*; and Lu, W. Development and validation of a highly sensitive LC-？MS？/MS method for the determination of dexamethasone in nude mice plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2015, 29(4), 578-83.
20. Shao, XY^#; Li, J^#; Wang, SY; Chen, GP; Xu, JJ; Ji, XW; Li, L; Lu, W; Zhou, TY*. Exogenous dopamine induces dehydroepiandrosterone sulfotranferase (rSULT2A1) in rat liver and changes the pharmacokinetic profile of moxifloxacin in rats. Drug Metab Pharmacok . 2015, 30, 97-104.
21. Li, XG; Zhao, ZG; Li, L; Zhou, TY*; and Lu, W*. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats. Drug Deliv. 2015, 22(1), 86–93.
22. Shao, XY; Li, J; Wang, SY; Chen, GP; Xu, JJ; Ji, XW; Li, L; Lu, W; Zhou, TY*. Comparison of dopamine with levodopa in the induction of aryl sulfotransferases and estrogen sulfotransferase in rat liver. J Chinese Pharm Sci. 2014, 23(7), 471-479.
23. Xu, JJ; Wang, SY; Chen, Y; Chen, GP; Li ZQ; Shao, XY; Li, L; Lu, W; Zhou, TY*. Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells. Acta Pharmacol Sin . 2014, 35(7), 889-898.
24. Ji, XW; Li, RT; Li, ZQ; Li, L; Shao, XY; Wang, SY; Yuan, Y; Zhou, TY*; Lu, W*. Inhibition of autophosphorylation of EGFR plays an important role in the anti-breast cancer efficacy of a dithiocarbamate derivative TM208. Acta Pharmacol Sin. 2014, 35, 239–247.
25. Li, MY; Li, HQ; Cheng, XL; Wang, XP; Li, L; Zhou, TY*, and Lu, W*. Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction between Erlotinib and Gemcitabine. Pharm Res . 2013, 30, 1400-1408.
26. Zhou, TY; Huang, CQ; Chen, Y; Xu, JJ; Shanbhag, PD; Chen, GP. Methamphetamine Regulation of Sulfotransferase 1A1 and 2A1 Expression in Rat Brain Sections. Neurotoxicology . 2013, 34, 212-218.
27. Wu, Q; Li, MY; Li, HQ; Deng, CH; Li, L; Zhou, TY*, and Lu, W*. Pharmacokinetic and pharmacodynamic study of erlotinib based upon phosphorylated epidermal growth factor receptor and tumor volume in human non-small cell lung cancer xenograft mouse mode. Acta Pharmacol Sin. 2013, 34, 1427–1436.
28. Cheng, XL; Guo,LP; Li, ZQ; Li, L; Zhou, TY*, Lu, W*. A HPLC method for simultaneous determination of 5-aminoimidazole-4-carboxamide riboside and its active metabolite 5-aminoimidazole-4-carboxamide ribotide in tumor-bearing nude mice plasma and its application to pharmacokinetics study. J Chromatogr B. 2013, 915–916, 64–70.
29. Zhou, TY; Chen, Y; Huang, CQ; Chen, GP. Caffeine induction of sulfotransferases in rat liver and intestine. JApplToxicol . 2012, 32, 804-809.
30. Zhou, X; Shang, DW; Zhang, TL; Li, L;Zhou, TY*; Lu, W*. Modeling of Angiotensin II-Angiotensin-(1-7) Counterbalance in Disease Progression in Spontaneously Hypertensive Rats Treated With/Without Perindopril. Pharmacol Res . 2012,66, 177-184.
31. Li, XG; Li, L; Wang, XP; Ren, YP; Zhou, TY*; Lu, W*. Application of Model-Based Methods to Characterize Exenatide-Loaded Double-Walled Microspheres: In Vivo Release, Pharmacokinetic/Pharmacodynamic Model, and In Vitro and In Vivo Correlation. J Pharm Sci . 2012, 101, 3946-3961.
32. Xu, JJ; Chen, Y; Li, L; Li, ZQ; Wang, CA;Zhou, TY*, Lu, W*. An improved HPLC method for the quantitation of 3′-phosphoadenosine 5′-phosphate (PAP) to assay sulfotransferase enzyme activity in HepG2 cells. J Pharmaceut Biomed Analysis . 2012, 62, 182-186.
33. Ji, XW; Chen, Y; Li, RT; Zhou, TY*; Lu, W*. A high-sensitivity LC-MS/MS method for determination of 4-methyl-piperazine-1-carbodithioc acid 3-cyano-3, 3-diphenylpropyl ester hydrochloride in rat plasma and its application to pharmacokinetics study. Biomed Chromatogr . 2012, 26, 1196-1201.
34. Li, XG; Li,L; Zhou,X; Chen,Y; Ren,YP; Zhou, TY*; Lu, W*. Pharmacokinetic/pharmacodynamic studies for exenatide in diabetic rats. Acta Pharmacol Sin. 2012, 33, 1379-1386.
35. Li, L; Li, ZQ; Deng, CH; Ning, MR; Li, HQ; Bi, SS; Zhou, TY* and Lu, W*. Mechanism-based Pharmacokinetic/Pharmacodynamic Model for CYP3A1/2 Induction by Dexamethasone in Rats. Acta Pharmacol Sin. 2012, 33, 127-136.
36. Li, MY; Wu, Q; Li, HQ; Ning, MR; Chen, Y; Li, L; Zhou, TY*; and Lu, W*. A high-sensitive LC-MS/MS method to determine the concentrations of erlotinib and its active metabolite OSI-420 in BALB/c nude mice simultaneously and its application to a pharmacokinetic study. J Chin Pharm Sci. 2012, 21, 296-303.
37. Chen, Y; Li, HQ; Xu, JJ; Jiu, XF; Deng, CH; Li, XG; Li, L; Xu, XQ; Zhou, TY*; and Lu, W*. Determination of metformin in diabetic rat plasma by an improved ion-pair high-performance liquid chromatography: Application to pharmacokinetic study, J Chin Pharm Sci. 2012, 21, 211-218.
38. Ning, MR; Li, L; Li, J; Li, ZQ; Li, RT; Zhou, TY*; Lu, W*. In-vitro screen of reversible and time-dependent inhibition of CYP3A by TM208 and TM209 in rat liver microsomes. Acta Pharm Sin B. 2012, 2, 179-185.
39. Shang, DW; Wang, XP; Zhao, XT; Huang, FM; Tian, GZ; Lu, W*; Zhou, TY*. Simultaneous determination of nitrendipine and hydrochlorothiazide in spontaneously hypertensive rat plasma using HPLC with on-line solid-phase extraction. J Chromatogr B . 2011, 879, 3459-3464．
40. Li, HQ; Li, MY; Li, ZQ; Li, L; Bi, SS; Deng, CH; Chen, R; Zhou, TY* and Lu, W*. New synthetic route of two active isomeric metabolites of erlotinib and their bioactivity studies against several tumor cell lines. Chin J Chem , 2011, 29, 1709-1714.
41. Jiu, XF; Shang, DW; Chen, Y; Li, XG; Wan, XM; Zhou, TY*; Lu, W*. A high performance liquid chromatography method for the quantitative determination assay of sitagliptin in rat plasma and its application in pharmacokinetics study. J Chin Pharm Sci. 2011, 20, 63-69.
42. Li, L; Li, ZQ; Li,HQ; Bi, SS; Li, Bo; Xu, JJ; Zhou, TY* and Lu, W*. Development of a quantitative real time PCR assay for absolute detection and quantification of CYP3A1 and CYP3A2 mRNA induction in rat liver. J Chin Pharm Sci. 2011, 20, 597-603.
43. Li, HQ; Chen, Y; Li, ZQ; Deng, CH; Li, L; Bi, SS; Li, MY; Zhou, TY*; Lu, W*. A high performance liquid chromatography method for the quantitative determination of erlotinib in the plasma of tumor bearing BALB/c nude mice and its application in a pharmacokinetic study. J Chin Pharm Sci. 2011, 20, 245-252.
44. Zhou, TY; Huang, CQ; Chen, Y; Shanbhag, PD; Chen, GP. Methamphetamine regulation of sulfotransferases in rat liver and brain. Am J Pharmacol Toxicol , 2010, 5, 125-132.
45. Zhou, TY; Li, XM; Ng, MTT; Wang, YF; Quek, NM; Luo, J; Yuan, WX; Tan, CH; Zeng, HQ; Li, TH. Synthesis and Characterization of Circular Structures of i-Motif Tagged with Fluoresceins. Bioconjugate Chem, 2009, 20, 644-647.
46. Zhou, TY; Wang, YF; Li, XM; Zhang, Q; Li, TH. Synthesis and characterization of a fluorescein-labeled circular G-quadruplex. B Chem Soc Jpn , 2006, 79(8), 1300-1302.
47. Zhou, TY; Chen, GS; Wang, YF; Zhang, Q; Yang, M; Li, TH. Synthesis of unimolecularly circular G-quadruplexes as prospective molecular probes. Nucleic Acids Res. 2004, 32, e173/1-e173/9.